 |
| 31-Jan-12 | Upgrade |
BB&T Capital Mkts |
Hold → Buy |
|
|
| 14-Jul-11 | Initiated |
BB&T Capital Mkts |
Hold |
|
|
| 25-Oct-10 | Downgrade |
Oppenheimer |
Outperform → Perform |
$29 → $22 |
|
| 28-Apr-10 | Reiterated |
Oppenheimer |
Outperform |
$21 → $29 |
|
| 26-Jan-10 | Reiterated |
Barclays Capital |
Overweight |
$17 → $18 |
|
| 13-Oct-09 | Reiterated |
Jefferies & Co |
Buy |
$15 → $17 |
|
| 29-Apr-09 | Reiterated |
Jefferies & Co |
Buy |
$14 → $13 |
|
| 02-Feb-09 | Upgrade |
Wachovia |
Mkt Perform → Outperform |
|
|
| 28-Jan-09 | Reiterated |
Jefferies & Co |
Buy |
$11 → $12 |
|
| 13-Jan-09 | Reiterated |
Jefferies & Co |
Buy |
$10.50 → $11 |
|
| 13-Jan-09 | Reiterated |
Barclays Capital |
Equal Weight |
$19 → $11 |
|
| 23-Dec-08 | Initiated |
Piper Jaffray |
Neutral |
|
|
| 17-Nov-08 | Upgrade |
Jefferies & Co |
Hold → Buy |
$13 → $10.50 |
|
| 09-Sep-08 | Reiterated |
Lehman Brothers |
Equal-Weight |
$27 → $29 |
|
| 12-Aug-08 | Downgrade |
Jefferies & Co |
Buy → Hold |
|
|
| 07-Aug-08 | Reiterated |
Ladenburg Thalmann |
Buy |
$31 → $38 |
|
| 17-Jul-08 | Initiated |
Ladenburg Thalmann |
Buy |
$31 |
|
| 24-Apr-08 | Reiterated |
Lehman Brothers |
Equal-Weight |
$25 → $27 |
|
| 22-Apr-08 | Upgrade |
First Analysis Sec |
Equal-Weight → Overweight |
|
|
| 11-Apr-08 | Reiterated |
Lehman Brothers |
Equal-weight |
$50 → $25 |
|
|
|
| 13-May-13 06:15PM | Cramer: This Fresh-Faced IPO Still a Buy at CNBC |
| 01:08AM | Is PAREXEL International a Cash Machine? at Motley Fool |
| 10-May-13 01:04PM | PAREXEL INTERNATIONAL CORP Financials EDGAR Online Financials |
| 09-May-13 06:56PM | Quintiles Climbs 5% In Debut In A Busy Day, Week For IPOs Investor's Business Daily |
| 11:45AM | Quintiles IPO Cleans Up As New Issues Multiply at Investor's Business Daily |
| 11:21AM | Quintiles IPO Cleans Up As New Issues Multiply at Investor's Business Daily |
| 11:13AM | Pharmaceutical services provider Quintiles surges on first day of trading at theflyonthewall.com |
| 06-May-13 02:20PM | Quintiles, PennyMac, Cyan Lead Large IPO Pack at Investor's Business Daily |
| 08:39AM | PAREXEL INTERNATIONAL CORP Files SEC form 10-Q, Quarterly Report EDGAR Online |
| 02-May-13 01:00PM | Charles River Misses Estimates in 1Q Zacks |
| 01-May-13 01:53PM | Stocks In Give-Back Mode; Spirit Air Flies, MasterCard Off at Investor's Business Daily +5.13% |
| 01:40PM | PAREXEL International Management Discusses Q3 2013 Results - Earnings Call Transcript at Seeking Alpha |
| 01:03PM | Today's Top Performers In Health Services at TheStreet |
| 10:00AM | PAREXEL International Earnings Call scheduled for 10:00 am ET today CCBN |
| 09:50AM | PAREXEL International Earnings Call scheduled for 10:00 am ET today CCBN |
| 01:51AM | PAREXEL INTERNATIONAL CORP Files SEC form 8-K, Results of Operations and Financial Condition EDGAR Online |
| 30-Apr-13 06:14PM | PAREXEL Makes an Acquisition at Motley Fool |
| 05:22PM | Parexel International Earnings: Everything You Must Know Now at Wall St. Cheat Sheet |
| 04:20PM | PAREXEL International Reports Third Quarter Fiscal Year 2013 Results PR Newswire |
| 04:06PM | InPlay: PAREXEL announces acquisition of HERON Group for ~ $24 mln Briefing.com |
| 04:02PM | PAREXEL International Announces Acquisition of HERON Group LTD, A Leading Commercialization Consultancy PR Newswire |
| 07:07AM | Q3 2013 PAREXEL International Earnings Release - After Market Close CCBN |
| 26-Apr-13 12:39PM | David Ferreiro, Executive Director and Senior Analyst at Oppenheimer & Co. Inc., Interviews with The Wall Street Transcript: Opportunities in Hepatitis C and Genomic Technologies Wall Street Transcript |
| 24-Apr-13 06:00AM | PAREXEL Honored with 2013 "Partnership Pioneers of the Year" Award PR Newswire |
| 22-Apr-13 08:00AM | New PAREXEL Report Defines The Next Generation Of Strategic Partnerships Between CROs And Biopharmaceutical Industry PR Newswire |
| 05-Apr-13 06:08PM | New Version of IMPACT CTMS in Market Zacks |
| 04-Apr-13 02:55PM | Parexel Grows Earnings With Big Pharma Partnerships at Investor's Business Daily |
| 03-Apr-13 06:00AM | Perceptive Informatics Improves Clinical Trial Management With New Release Of IMPACT® CTMS Solution PR Newswire |
| 02-Apr-13 09:45AM | PAREXEL Announces Date of Third Quarter Fiscal Year 2013 Earnings Release and Conference Call PR Newswire |
| 28-Mar-13 08:34AM | PAREXEL INTERNATIONAL CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Finan EDGAR Online |
| 22-Mar-13 05:04PM | PAREXEL International Larger Than S&P 500 Component Apollo Group at Forbes |
| 20-Mar-13 01:05AM | Has PAREXEL International Made You Any Real Money? at Motley Fool |
| 19-Mar-13 12:47PM | Europe Medical Device Space Less Volatile Than the U.S. Due to Domestic Market Being More Exposed to Swings in Consumer Sentiment, says Matt Miksic, Managing Director and Senior Research Analyst at Piper Jaffray & Co. Wall Street Transcript |
| 08:28AM | PAREXEL INTERNATIONAL CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and E EDGAR Online |
| 15-Mar-13 12:35PM | Parexel Stock Hits New High As Buyback Ramps Up at Investor's Business Daily |
| 08:39AM | Texas Instruments Hurt and 4 Stocks At 52-Week Highs at Wall St. Cheat Sheet |
| 14-Mar-13 05:03PM | InPlay: PAREXEL announces a new $50 mln accelerated share repurchase agreement and a new $50 mln 10b5-1 trading plan Briefing.com |
| 04:02PM | PAREXEL International Provides Update On Share Repurchase Program, Announces A New $50 Million Accelerated Share Repurchase Agreement And A New $50 Million 10b5-1 Trading Plan PR Newswire |
| 12-Mar-13 03:50PM | PAREXEL International Corporation Presents at Barclays Global Healthcare Conference, Mar-12-2013 02:00 PM at Seeking Alpha |
| 08-Mar-13 10:00AM | Movers and Shakers: A look at who is coming and going at bizjournals.com |
| 05-Mar-13 04:37PM | Parexel Punches To All-Time High After Pullback at Investor's Business Daily |
| 04-Mar-13 01:06AM | Some Numbers at PAREXEL International that Make Your Stock Look Good at Motley Fool |
| 28-Feb-13 06:00AM | PAREXEL International To Present At Raymond James Investors Conference And Barclays Capital Healthcare Conference PR Newswire |
| 27-Feb-13 07:40PM | PAREXEL International Corporation Presents at Citi 2013 Global Healthcare Conference, Feb-27-2013 10:20 AM at Seeking Alpha |
| 25-Feb-13 04:34PM | PAREXEL INTERNATIONAL CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and E EDGAR Online |
| 20-Feb-13 06:00AM | PAREXEL International To Present At Citi Global Healthcare Conference PR Newswire |
| 19-Feb-13 02:27PM | ESRX Reports In-Line 4Q Earnings Zacks |
| 14-Feb-13 03:02PM | Here's How PAREXEL International May Be Failing You at Motley Fool |
| 02:56PM | Mixed 4Q for Charles River Zacks |
| 13-Feb-13 05:17PM | Parexel International In Buying Range From Flat Base at Investor's Business Daily |
| 07-Feb-13 04:22PM | Short Candidates for Contrarians, Part 3 at Motley Fool |
| 01:04PM | PAREXEL INTERNATIONAL CORP Financials EDGAR Online Financials |
| 04-Feb-13 06:00AM | PAREXEL INTERNATIONAL CORP Files SEC form 10-Q, Quarterly Report EDGAR Online |
| 31-Jan-13 10:49AM | Concur Tech Sees Solid Demand and 4 Stock Analyses Turning Heads at Wall St. Cheat Sheet |
| 30-Jan-13 12:04PM | 5 Stocks Pushing The Health Care Sector Lower at TheStreet |
| 12:02PM | Parexel Stock Falls Despite Q2 Beat As Margins Shrink at Investor's Business Daily |
| 10:42AM | Madison Square Garden Risk Declines and 4 Stock Analyses Not to Miss at Wall St. Cheat Sheet |
| 10:40AM | Early Gains Become Mild Losses; CommVault Systems Grabs New High at Investor's Business Daily |
| 10:00AM | PAREXEL International Earnings Call scheduled for 10:00 am ET today CCBN |
| 09:45AM | PAREXEL International Earnings Call scheduled for 10:00 am ET today CCBN |
| 09:05AM | PAREXEL Q2 beat and raise of poor quality, says Jefferies theflyonthewall.com |
| 06:00AM | PAREXEL INTERNATIONAL CORP Files SEC form 8-K, Results of Operations and Financial Condition EDGAR Online |
| 29-Jan-13 05:51PM | Parexel posts higher profit, lifts outlook AP |
| 04:44PM | PAREXEL ups 2013 revenue and earnings expectations at bizjournals.com |
| 04:13PM | InPlay: PAREXEL beats by $0.08, beats on revs; guides Q3 and FY13 above consensus Briefing.com |
| 04:02PM | PAREXEL International Reports Second Quarter Fiscal Year 2013 Results PR Newswire |
| 08:05AM | Parexel Q2 Earnings Expected To Pop 43% at Investor's Business Daily |
| 07:07AM | Q2 2013 PAREXEL International Earnings Release - After Market Close CCBN |
| 28-Jan-13 03:44PM | PAREXEL INTERNATIONAL CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Finan EDGAR Online |
| 08:08AM | All-Front Easy Beat for Covance Zacks |
| 23-Jan-13 08:13AM | New chair of global CRO association to focus on training researchers at bizjournals.com |
| 22-Jan-13 02:08PM | Parexel names new president of Perceptive Informatics unit at bizjournals.com |
| 08:42AM | PAREXEL Announces Xavier Flinois as Incoming President of Perceptive Informatics PR Newswire |
| 10-Jan-13 08:47AM | Lionsgate Strikes Agreement With American Greetings and 4 Stocks Enjoying 52-Week Highs at Wall St. Cheat Sheet |
| 07:47AM | PAREXEL Chairman and CEO Josef von Rickenbach Elected 2013 ACRO Chairman PR Newswire |
| 04-Jan-13 06:00AM | PAREXEL International To Present At J.P. Morgan Healthcare Conference PR Newswire |
| 03-Jan-13 03:25PM | These 3 Stocks Have A History Of Q1 Gains at Seeking Alpha |
| 02:38PM | PRXL Closes Buyout, Yields Outlook (revised) Zacks |
| 09:45AM | PAREXEL Announces Date Of Second Quarter Fiscal Year 2013 Earnings Release And Conference Call PR Newswire |
| 02-Jan-13 08:20AM | Ahead of the Bell: Parexel stock receives upgrade AP +5.17% |
| 05:44AM | PAREXEL upgraded to Buy from Neutral at Citigroup theflyonthewall.com |
| 31-Dec-12 08:57AM | Strengthening Moats Mean Improving Returns For CRO Investors at Seeking Alpha |
| 07:00AM | Strengthening Moats Mean Improving Returns for CRO Investors Morningstar |
| 28-Dec-12 12:30PM | Sanofi SA and More Big Movers in Healthcare on December 28, 2012 at Investopedia |
| 11:48AM | PRXL Closes Buyout; Yields Outlook Zacks |
| 27-Dec-12 03:39PM | PAREXEL INTERNATIONAL CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Finan EDGAR Online |
| 01:14PM | Parexel acquires Liquent for $72M, raises earnings expectations at bizjournals.com |
| 01:10PM | Parexel buys life sciences software maker Liquent at bizjournals.com |
| 12:30PM | Regeneron Pharmaceuticals and Other Healthcare Stocks Making Big Moves on December 27, 2012 at Investopedia |
| 12:05PM | Stocks Give Up More Ground; Nasdaq, S&P 500 Break Support Levels at Investor's Business Daily |
| 08:32AM | InPlay: PAREXEL raises Q2 and FY13 revenue guidance above consensus, announces acquisition of Liquent Briefing.com |
| 08:30AM | PAREXEL International Announces Acquisition of Liquent, Inc., and Updates Financial Guidance PR Newswire |
| 20-Dec-12 04:58PM | PAREXEL International Moves Up In Market Cap Rank, Passing Advanced Micro Devices at Forbes |
| 19-Dec-12 12:30PM | Healthcare Stocks, Including Regeneron Pharmaceuticals, Making Big Moves on December 19, 2012 at Investopedia |
| 12-Dec-12 04:09PM | PAREXEL INTERNATIONAL CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Holders EDGAR Online |
| 10-Dec-12 06:00AM | Perceptive Informatics Opens First Customer Care Office in China PR Newswire |
| 05-Dec-12 06:00AM | PAREXEL International To Present At Oppenheimer Healthcare Conference PR Newswire |
| 04-Dec-12 06:00AM | Perceptive Informatics' Randomization Technologies Used in More Than 3,000 Clinical Trials for Improved Data Access and Faster Decision Making PR Newswire |
| 03-Dec-12 09:08AM | Here's 1 Reason PAREXEL International Looks Weak at Motley Fool |
| 29-Nov-12 02:05PM | Is Parexel Int'l Passing The Test For Investors? at Investor's Business Daily |
|
|
| PAREXEL International Corporation, a biopharmaceutical services company, provides clinical research, medical communications, consulting, commercialization, and advanced technology products and services to the pharmaceutical, biotechnology, and medical device industries worldwide. The company operates in three segments: Clinical Research Services (CRS), PAREXEL Consulting and Medical Communications Services (PCMS), and Perceptive Informatics (Perceptive). The CRS segment offers clinical trials management, observational studies, patient/disease registries and post-marketing surveillance, data management and biostatistics, epidemiology and health economics/outcomes research, clinical logistics, pharmacovigilance, and clinical pharmacology, as well as related medical affairs, patient recruitment, and investigator site services. This segment manages various aspects of clinical trials, including study and protocol design, case report form design, paper or electronic questionnaires design, patient enrollment, study monitoring and data collection, data analysis, report writing, and medical services. The PCMS segment provides technical expertise and advice in various areas, such as drug development, regulatory affairs, product pricing and reimbursement, and good manufacturing practice compliance consulting; and market development, product development, and targeted communications services in support of product launch. Its consultants also identify alternatives and propose solutions to address clients' product development, registration, and commercialization issues. In addition, this segment provides reimbursement and market access services. The Perceptive segment provides information technology solutions comprising medical imaging and systems integration services; ClinPhone RTSM, CTMS, and DataLabs EDC products; Web-based portals; and patient diary applications. The company was founded in 1983 and is headquartered in Waltham, Massachusetts. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| CALLOW A DANA JR | Director | May 14 | Sale | 46.39 | 8,000 | 371,120 | 40,713 | May 15 01:53 PM | | GOLDBERG MARK A | President & COO | May 13 | Option Exercise | 21.97 | 18,650 | 409,741 | 160,642 | May 14 10:43 AM | | GOLDBERG MARK A | President & COO | May 13 | Sale | 45.19 | 28,887 | 1,305,404 | 131,755 | May 14 10:43 AM | | Cooper Anita | Senior VP, CRS | May 10 | Option Exercise | 23.06 | 10,000 | 230,600 | 30,086 | May 14 08:22 AM | | Cooper Anita | Senior VP, CRS | May 10 | Sale | 44.99 | 10,000 | 449,900 | 20,086 | May 14 08:22 AM | | SCHNEIDER ULF I | SVP & Chief Admin. Officer | May 09 | Sale | 44.54 | 20,510 | 913,515 | 1,500 | May 14 08:34 AM | | SCHNEIDER ULF I | SVP & Chief Admin. Officer | May 08 | Sale | 44.53 | 30,000 | 1,335,900 | 20,293 | May 09 10:53 AM | | BATT DOUGLAS A | SVP, General Counsel & Sec. | May 07 | Option Exercise | 30.18 | 5,000 | 150,900 | 64,178 | May 08 01:40 PM | | WINSCHEL JAMES F JR | Senior VP & CFO | May 07 | Sale | 44.31 | 824 | 36,511 | 15,120 | May 14 01:32 PM | | VON RICKENBACH JOSEF H | Chairman & CEO | May 07 | Sale | 44.39 | 72,000 | 3,196,080 | 573,651 | May 08 01:44 PM | | SCHNEIDER ULF I | SVP & Chief Admin. Officer | May 07 | Sale | 44.03 | 14,774 | 650,499 | 50,293 | May 08 01:42 PM | | BATT DOUGLAS A | SVP, General Counsel & Sec. | May 07 | Sale | 44.36 | 5,000 | 221,800 | 59,178 | May 08 01:40 PM | | Saarony Gadi | Corp. Sr. VP, CRS | May 06 | Option Exercise | 20.15 | 10,000 | 201,450 | 14,900 | May 08 01:43 PM | | SCHNEIDER ULF I | SVP & Chief Admin. Officer | May 06 | Sale | 44.00 | 25,226 | 1,109,944 | 65,067 | May 08 01:42 PM | | VON RICKENBACH JOSEF H | Chairman & CEO | May 06 | Sale | 43.88 | 28,000 | 1,228,640 | 645,651 | May 08 01:44 PM | | Saarony Gadi | Corp. Sr. VP, CRS | May 06 | Sale | 44.07 | 10,000 | 440,700 | 4,900 | May 08 01:43 PM | | Holdener Eduard E. | Director | May 03 | Sale | 43.70 | 12,000 | 524,448 | 16,012 | May 06 02:34 PM | | CALLOW A DANA JR | Director | Mar 05 | Sale | 36.31 | 5,000 | 181,550 | 48,713 | Mar 06 02:35 PM | | Saarony Gadi | Corp. Sr. VP, CRS | Mar 01 | Option Exercise | 20.30 | 10,000 | 203,000 | 14,900 | Mar 05 12:27 PM | | Saarony Gadi | Corp. Sr. VP, CRS | Mar 01 | Sale | 34.82 | 10,000 | 348,200 | 4,900 | Mar 05 12:27 PM | | FORTUNE PATRICK J | Director | Feb 22 | Option Exercise | 9.69 | 3,336 | 32,326 | 32,518 | Feb 25 05:03 PM | | FORTUNE PATRICK J | Director | Feb 22 | Sale | 34.01 | 3,336 | 113,457 | 29,182 | Feb 25 05:03 PM | | Zane Ellen M | Director | Feb 20 | Sale | 34.25 | 30,000 | 1,027,500 | 38,778 | Feb 21 01:35 PM | | Brykman Kurt Arthur | President, PACE and PCMS | Feb 19 | Option Exercise | 30.18 | 25,000 | 754,500 | 90,511 | Feb 21 09:06 AM | | Brykman Kurt Arthur | President, PACE and PCMS | Feb 19 | Sale | 34.45 | 25,000 | 861,250 | 65,511 | Feb 21 09:06 AM | | LINDOP CHRISTOPHER J | Director | Feb 12 | Sale | 34.40 | 2,543 | 87,479 | 37,211 | Feb 13 01:59 PM | | Cooper Anita | Corp. Senior VP, GRO | Feb 08 | Option Exercise | 10.13 | 10,000 | 101,300 | 30,086 | Feb 11 12:15 PM | | Cooper Anita | Corp. Senior VP, GRO | Feb 08 | Sale | 34.00 | 10,000 | 340,000 | 20,086 | Feb 11 12:15 PM | | WINSCHEL JAMES F JR | Senior VP & CFO | Dec 31 | Option Exercise | 12.55 | 22,707 | 284,973 | 203,094 | Jan 02 11:21 AM | | Saarony Gadi | Corp. Sr. VP, CRS | Nov 29 | Option Exercise | 20.26 | 6,200 | 125,612 | 11,100 | Nov 30 01:32 PM | | Saarony Gadi | Corp. Sr. VP, CRS | Nov 29 | Sale | 32.49 | 6,200 | 201,438 | 4,900 | Nov 30 01:32 PM | | GOLDBERG MARK A | President & COO | Nov 28 | Option Exercise | 12.55 | 11,675 | 146,521 | 153,667 | Nov 30 01:29 PM | | GOLDBERG MARK A | President & COO | Nov 28 | Sale | 32.01 | 11,675 | 373,717 | 141,992 | Nov 30 01:29 PM | | VON RICKENBACH JOSEF H | Chairman & CEO | Nov 26 | Sale | 31.64 | 110,489 | 3,495,872 | 673,325 | Nov 28 11:36 AM | | VON RICKENBACH JOSEF H | Chairman & CEO | Nov 21 | Option Exercise | 12.55 | 36,550 | 458,703 | 807,390 | Nov 26 02:25 PM | | Saarony Gadi | Corp. Sr. VP, CRS | Nov 19 | Option Exercise | 20.30 | 10,000 | 203,000 | 14,900 | Nov 20 01:26 PM | | Saarony Gadi | Corp. Sr. VP, CRS | Nov 19 | Sale | 31.99 | 10,000 | 319,900 | 4,900 | Nov 20 01:26 PM | | CALLOW A DANA JR | Director | Nov 09 | Option Exercise | 10.45 | 20,000 | 209,000 | 92,256 | Nov 13 09:05 AM | | CALLOW A DANA JR | Director | Nov 09 | Sale | 30.11 | 38,543 | 1,160,530 | 53,713 | Nov 13 09:05 AM | | GOLDBERG MARK A | President & COO | Nov 06 | Option Exercise | 12.55 | 5,000 | 62,750 | 146,992 | Nov 07 11:06 AM | | GOLDBERG MARK A | President & COO | Nov 06 | Sale | 31.00 | 5,000 | 155,000 | 141,992 | Nov 07 11:06 AM | | Brykman Kurt Arthur | President, PACE and PCMS | Nov 05 | Option Exercise | 18.72 | 1,281 | 23,975 | 78,217 | Nov 07 11:04 AM | | BATT DOUGLAS A | SVP, General Counsel & Sec. | Nov 05 | Sale | 30.49 | 4,600 | 140,254 | 59,178 | Nov 07 11:05 AM | | Brykman Kurt Arthur | President, PACE and PCMS | Nov 05 | Sale | 30.56 | 12,706 | 388,295 | 65,511 | Nov 07 11:04 AM | | Brykman Kurt Arthur | President, PACE and PCMS | Nov 02 | Option Exercise | 18.21 | 21,019 | 382,731 | 97,955 | Nov 06 07:41 AM | | VON RICKENBACH JOSEF H | Chairman & CEO | Nov 02 | Option Exercise | 12.55 | 50,000 | 627,500 | 803,709 | Nov 06 07:43 AM | | LOVE RICHARD L | Director | Nov 02 | Sale | 30.16 | 2,000 | 60,320 | 103,741 | Nov 06 08:21 AM | | Brykman Kurt Arthur | President, PACE and PCMS | Nov 02 | Sale | 30.13 | 21,019 | 633,302 | 76,936 | Nov 06 07:41 AM | | BATT DOUGLAS A | SVP, General Counsel & Sec. | Nov 02 | Sale | 30.48 | 7,176 | 218,724 | 63,778 | Nov 06 07:44 AM | | GOLDBERG MARK A | President & COO | Oct 04 | Option Exercise | 12.55 | 5,000 | 62,750 | 146,992 | Oct 05 04:41 PM | | GOLDBERG MARK A | President & COO | Oct 04 | Sale | 32.00 | 5,000 | 160,000 | 141,992 | Oct 05 04:41 PM | | LINDOP CHRISTOPHER J | Director | Sep 25 | Sale | 30.92 | 5,112 | 158,063 | 40,454 | Sep 26 12:57 PM | | SCHNEIDER ULF I | SVP & Chief Admin. Officer | Sep 14 | Sale | 30.69 | 35,700 | 1,095,633 | 90,025 | Sep 17 04:23 PM | | LINDOP CHRISTOPHER J | Director | Sep 11 | Sale | 30.10 | 7,800 | 234,780 | 40,355 | Sep 12 02:23 PM | | SCHNEIDER ULF I | SVP & Chief Admin. Officer | Sep 10 | Option Exercise | 0.00 | 19,000 | 0 | 176,235 | Sep 12 02:36 PM | | GOLDBERG MARK A | President & COO | Sep 06 | Option Exercise | 12.55 | 10,000 | 125,500 | 146,382 | Sep 07 10:58 AM | | GOLDBERG MARK A | President & COO | Sep 06 | Sale | 30.00 | 10,000 | 300,000 | 136,382 | Sep 07 10:58 AM | | VON RICKENBACH JOSEF H | Chairman & CEO | Aug 28 | Option Exercise | 11.45 | 50,000 | 572,700 | 765,763 | Aug 29 12:40 PM | | Holdener Eduard E. | Director | Aug 24 | Sale | 26.92 | 15,000 | 403,800 | 31,801 | Aug 27 02:39 PM | | CALLOW A DANA JR | Director | Jun 27 | Option Exercise | 9.63 | 10,000 | 96,250 | 67,045 | Jun 29 08:58 AM | | Brykman Kurt Arthur | President, PACE and PCMS | Jun 08 | Option Exercise | 12.55 | 15,800 | 198,290 | 104,017 | Jun 11 02:42 PM | | Brykman Kurt Arthur | President, PACE and PCMS | Jun 08 | Sale | 26.66 | 26,800 | 714,488 | 77,217 | Jun 11 02:42 PM | | VON RICKENBACH JOSEF H | Chairman & CEO | Jun 07 | Option Exercise | 9.81 | 40,000 | 392,400 | 738,433 | Jun 11 02:33 PM |
|
|
|
|
|
|
